Price movement over the last 24 hours
Alcon AG vs Chewy Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Chewy Inc trades at $20.63 (market cap $8.49B). The key difference: Alcon AG is far larger — about 3.9× Chewy Inc's market cap, and Alcon AG pays a 0.54% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| ALC | CHWY | |
|---|---|---|
Market Cap | $32.69B | $8.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $42.33 |
52-Week Low | $62.02 | $17.51 |
Enterprise Value | $36.28B | $8.45B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Chewy (CHWY) trades at $20.73, down 0.58% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported $11.86B in revenue for 2025 with a net income margin of 1.99%, showing improved profitability from prior years. Recent news highlights market share gains through its Autoship program and expansion into pet healthcare services, though the stock faces pressure from lowered 2026 growth expectations.
The outlook remains positive with an 81.58% buy rating from analysts and a $34.92 consensus price target, suggesting significant upside. Key risks include competitive pressures in the pet care sector and execution challenges in integrating new veterinary services. Investors should weigh strong customer loyalty and recurring revenue streams against near-term volatility and margin pressures.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →